stockrow
Saturday 7 November 2026
Export OTLK’s income statement to Excel — free account
Outlook Therapeutics, Inc.
OTLK Healthcare Biotechnology
Outlook Therapeutics, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $1.4 million.
- Revenue
- −99.4%
- EPS
- +72.7%
- Free cash flow
- −76.5%
- Total debt
- −47.1%
Quarter to June 2026, against a year earlier
0.43
0.01
−2.27%
Follow OTLK
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.00 | 51.59 | 15.70 | 4.70 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.35) | (2.20) | (6.37) | (2.98) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
(202.43) | 109.30 | 23.69 | 10.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.19) | (0.77) | (2.57) | (1.53) | |
EV/FCF |
(4.16) | (0.77) | (2.55) | (1.51) | |
Quick Ratio |
0.45 | 0.27 | 0.18 | 0.21 | |
Current Ratio |
0.81 | 0.54 | 0.35 | 0.38 | |
Net Debt/EBITDA |
(0.65) | (1.37) | (2.08) | (1.26) | |
Debt/Assets |
69.61% | 123.19% | 201.00% | 161.14% | |
Debt/Equity |
(1.75) | (0.93) | (0.95) | (0.93) | |
Asset Turnover |
(0.05) | 0.02 | 0.34 | 0.33 | |
Operating CF/Net income |
1.03 | 1.76 | 0.65 | 0.93 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | — | (80.42) | |
Research and Development Expense of Revenue |
37,368.97% | 3,532.57% | (300.91%) | (6,512.85%) | |
Selling, General and Administrative Expense of Revenue |
86,790.80% | 7,460.44% | (713.04%) | (11,250.00%) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
9,100.00% | 594.51% | (72.96%) | (1,983.22%) | |
Graham Net Nets |
(0.06) | (1.74) | (0.42) | (0.91) | |
Graham Number |
1.21 | 3.17 | 6.25 | 5.79 | |
Earnings Yield |
(54.22%) | (601.00%) | (171.65%) | (152.08%) | |
Free Cash Flow Yield |
(26.03%) | (276.29%) | (59.12%) | (141.71%) | |
Revenue per Share |
0.00 | 0.00 | (0.02) | 0.00 | |
Operating CF per Share |
(0.15) | (0.10) | (0.25) | (0.36) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.15) | (0.10) | (0.25) | (0.36) | |
Cash per Share |
0.08 | 0.09 | 0.14 | 0.23 | |
Shareholders Equity per Share |
(0.08) | (0.35) | (0.64) | (0.92) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.08) | (0.35) | (0.64) | (0.92) | |
Free Cash Flow |
(21.01) | (7.83) | (14.94) | (12.38) | |
Working Capital |
(5.51) | (17.98) | (31.89) | (28.43) | |
Net Current Asset Value |
(13.41) | (29.98) | (39.62) | (33.38) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.70 | 1.38 | 0.33 | 2.49 | |
Average Payables |
8.53 | 10.70 | 9.76 | 9.08 | |
Average Inventory |
4.59 | 3.47 | 3.28 | — | |
Average Assets |
24.29 | 20.48 | 17.62 | 23.70 | |
Average Common Equity |
(23.79) | (30.73) | (44.42) | (52.63) |
Columns are period end dates · fundamentals updated 26 Oct 2026